

CORRECTION



Correction to: CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease

Hemalatha G. Rangarajan , Sara A. Crowell, Alison S. Towerman and Shalini S. Shenoy

© The Author(s), under exclusive licence to Springer Nature Limited 2022

Bone Marrow Transplantation (2022) 57:1855; <https://doi.org/10.1038/s41409-022-01854-9>

Correction to: *Bone Marrow Transplantation* <https://doi.org/10.1038/s41409-022-01749-9>, published online 07 July 2022

In the online version of article we state “Following informed consent, all three patients received fludarabine 100 mg/m² on days -6 to -3, cyclophosphamide 60 mg/kg on days -3 and -2, and rabbit anti-thymocyte 16 globulin (r-ATG) 10 mg/kg on days -5 to -2”

It should be read as :

Following informed consent, all three patients received fludarabine 25 mg/m² on days -6 to -2 (total dose 125 mg/m²), cyclophosphamide 60 mg/kg on days -3 and -2 (total dose 120 mg/kg) and rabbit anti-thymocyte globulin (r-ATG) 2.5 mg/kg on days -5 to -2 (total dose 10 mg/kg).

The original article has been corrected.